We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-14.51%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.25B
AUM Growth
-$409M
Cap. Flow
-$35.9M
Cap. Flow %
-2.87%
Top 10 Hldgs %
50.14%
Holding
212
New
40
Increased
31
Reduced
43
Closed
54

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$43.5M
2
RGNX icon
Regenxbio
RGNX
+$19.9M
3
ARAV
Aravive, Inc. Common Stock
ARAV
+$15.6M
4
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
+$14.2M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$12.7M

Top Sells

Rank Stock Value
1
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$19M
2
AGN
Allergan plc
AGN
+$18M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$17.5M
4
CBPO
China Biologic Products Holdings, Inc.
CBPO
+$17M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 77.95%
2 Consumer Discretionary 0.07%
3 Financials 0.04%
4 Energy 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STLA icon
101
Stellantis
STLA
$17.4B
$819K 0.07%
95,090
– –
ANIP icon
102
ANI Pharmaceuticals
ANIP
$1.86B
$761K 0.06%
19,256
-307,901
-94% -$17.5M
STML
103
DELISTED
Stemline Therapeutics, Inc.
STML
$694K 0.06%
78,603
-642
-0.8% -$6.74K
GRCE
104
Grace Therapeutics
GRCE
$33.8M
$626K 0.05%
4,928
– –
XNCR icon
105
PUT
Xencor
XNCR
$1.45B
$612K 0.05%
+50,000
New +$979K
VIRX
106
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$567K 0.05%
3,333
– –
GLMD icon
107
Galmed Pharmaceuticals
GLMD
$4.62M
$557K 0.04%
417
– –
TBT icon
108
ProShares Trust UltraShort Lehman 20+ Year Treasury
TBT
$300M
$520K 0.04%
+12,000
New +$550K
DRNA
109
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$411K 0.03%
50,000
– –
TRIL
110
DELISTED
Trillium Therapeutics Inc.
TRIL
$391K 0.03%
30,000
– –
OTIC
111
DELISTED
Otonomy, Inc.
OTIC
$364K 0.03%
185,368
-182,018
-50% -$4.31M
AKAO
112
DELISTED
Achaogen Inc
AKAO
$346K 0.03%
60,000
– –
APYX icon
113
Apyx Medical
APYX
$162M
$322K 0.03%
162,700
-10,000
-6% -$22.9K
ARMP icon
114
Armata Pharmaceuticals
ARMP
$168M
$316K 0.03%
+571
New +$522K
NVO
115
Novo Nordisk
NVO
$228B
$290K 0.02%
10,680
+6,000
+128% +$170K
SYNH
116
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$290K 0.02%
7,261
– –
AET
117
DELISTED
Aetna Inc
AET
$283K 0.02%
2,586
-7,500
-74% -$866K
LHCG
118
DELISTED
LHC Group LLC
LHCG
$265K 0.02%
5,917
– –
EYPT icon
119
EyePoint Inc
EYPT
$999M
$257K 0.02%
31,500
– –
ITGR icon
120
Integer Holdings
ITGR
$3.39B
$248K 0.02%
4,817
– –
GILD icon
121
Gilead Sciences
GILD
$165B
$241K 0.02%
2,457
– –
ADUS icon
122
Addus HomeCare
ADUS
$2.22B
$237K 0.02%
+7,601
New +$223K
HNT
123
DELISTED
HEALTH NET INC
HNT
$231K 0.02%
3,831
– –
EW icon
124
Edwards Lifesciences
EW
$49.4B
$213K 0.02%
+9,000
New +$217K
TARO
125
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$213K 0.02%
1,493
– –
3 4
5
6 7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Perceptive Advisors held 212 positions worth $1.25B, down 25% from $1.66B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q3 2015 filing shows 40 new, 31 increased, 43 reduced and 54 closed positions. Its largest new stake was Global Blood Therapeutics, Inc.: 921,800 shares worth $38.9M. The largest sale was ZS PHARMA INC COMS TK (DE), an estimated $19M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Perceptive Advisors's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 921,800 shares worth $38.9M.
  • Perceptive Advisors added most to Aravive, Inc. Common Stock in Q3 2015, an estimated $15.6M increase.
  • Perceptive Advisors's biggest Q3 2015 reduction was ANI Pharmaceuticals, cutting an estimated $17.5M.
  • Perceptive Advisors fully exited ZS PHARMA INC COMS TK (DE) in Q3 2015, selling an estimated $19M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.25B portfolio in Q3 2015.
  • Perceptive Advisors opened 40 new positions and closed 54 in Q3 2015.
  • Perceptive Advisors's portfolio value fell 25% quarter-over-quarter to $1.25B.

Based on Perceptive Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.